42545-63-1

Basic information

• Product Name: PYRIDIN-3-YLACETALDEHYDE
• Synonyms: PYRIDIN-3-YLACETALDEHYDE;3-Pyridineacetaldehyde;2-(pyrid-3-yl)acetaldehyde;2-(Pyridin-3-yl)acetaldehyde;2-(Pyridin-3-yl)
• CAS NO: 42545-63-1
• Molecular Formula: C₇H₇NO
• Molecular Weight: 121.14
• Mol File: 42545-63-1.mol

Chemical Properties

• Boiling Point: 234.8±15.0 °C(Predicted)
• Appearance: /
• Density: 1.074±0.06 g/cm3(Predicted)
• Storage Temp.: Inert atmosphere,Store in freezer, under -20°C
• PKA: 4.90±0.10(Predicted)
• CAS DataBase Reference: PYRIDIN-3-YLACETALDEHYDE(CAS DataBase Reference)
• NIST Chemistry Reference: PYRIDIN-3-YLACETALDEHYDE(42545-63-1)
• EPA Substance Registry System: PYRIDIN-3-YLACETALDEHYDE(42545-63-1)

Safety Data

• Hazardous Substances Data: 42545-63-1(Hazardous Substances Data)

Usage

Uses

Used in Pharmaceutical Industry:
PYRIDIN-3-YLACETALDEHYDE is used as a reagent for the preparation of a series of platelet-derived growth factor receptor tyrosine kinase (PDGF-RTK) inhibitors. These inhibitors play a crucial role in the treatment of various diseases, including cancer, by targeting the PDGF-RTK signaling pathway.
Used in Pain Management:
PYRIDIN-3-YLACETALDEHYDE is used as an intermediate in the synthesis of Pyridin-3-ylacetaldehyde Sodium Salt (P991755), which is a CB1/CB2 agonist. This agonist has potential applications in the treatment of chronic pain, as it interacts with the endocannabinoid system to provide pain relief.
Used in Chemical Synthesis:
PYRIDIN-3-YLACETALDEHYDE is used as a key intermediate in the synthesis of 3-Substituted quinoline derivatives. These derivatives have various applications in the pharmaceutical industry, including the development of new drugs and therapeutic agents.

Upstream product

• 39931-77-6 pyridin-3-yl-acetic acid ethyl ester 
• 217316-41-1 N-methoxy-N-methyl-2-(pyridin-3-yl)acetamide 
• 6293-56-7 3-pyridinylethanol 

Downstream Products

• 107772-61-2 C₁₄H₁₃NO₂S 
• 6443-85-2 3-pyridinylacetonitrile 

Relevant articles and documents

Synthesis and antitumor activity of novel pyridinium fullerene derivatives

Purpose: We have previously reported that some cationic fullerene derivatives exhibited anticancer activity, and they are expected to be a potential lead compound for an anti-drug resistant cancer agent. However, they are bis-adducts and a mixture of multiple regioisomers, which cannot be readily separated due to the variability of substituent positions on the fullerene cage. To overcome this issue, we evaluated the antiproliferative activities of a set of mono-adduct derivatives and examined their structure-activity relationship. In addition, the in vivo antitumor activity of selected derivatives was also examined. Methods: Nineteen pyridinium fullerene derivatives were newly designed and synthesized in this study. Their antiproliferative activities were evaluated using several cancer cell lines including drug-resistant cells. Furthermore, in vivo antitumor activity of several derivatives was investigated in mouse xenograft model of human lung cancer. Results: The derivatives inhibited the proliferation of cancer cell lines, including cisplatin-resistant cells and doxorubicin-resistant cells. It was also shown that compound 10 (10 μM), 13 (10 μM) and cis-14 (10 μM) induced the intracellular oxidative stress. In addition, compound 13 (20 mg/kg) and cis-14 (15 mg/kg) significantly exhibited antitumor activity in mouse xenograft model of human lung cancer. Conclusion: We synthesized a novel set of mono-adduct fullerene derivatives functionalized with pyridinium groups and found that most of them show potent antiproliferative activities against cancer cell lines and some of them show significant antitumor activities in vivo. We propose that these fullerene derivatives serve as the lead compounds for a novel type of antitumor agents.

CaCl2.2H2O assisted oxidation of alcohols with (NH4)2Cr2O7

CaCl2.2H2O has been found to be an efficient reagent for the acceleration of the oxidation of alcohols to their corresponding carbonyl compounds with (NH4)2Cr2O7 in solution and under solvent free conditions.

Antagonists of gonadotropin releasing hormone

There are disclosed compounds of formula (I) and pharmaceutically acceptable salts thereof which are useful as antagonists of GnRH and as such may be useful for the treatment of a variety of sex-hormone related and other conditions in both men and women.